Deciphering a short text in mid-10th century Greek bookhand - β???????
|
| Post date: 2021-03-05 03:36:33 |
| Views: 198 |
On the basis of two online images of a meticulously lettered paragraph in two early copies of Dioscorides' De Materia Medica - one smaller, colour one from the Morgan manuscript, and one larger, more distinct, black&white one from the Vienna manuscript - would anyone be able to help transcribe and possibly translate the text? (My previous appeal for a classical Japanese page found great help from the hive mind!)
The text pertains to the first illustration on the page, of a stag's head - the inscription next to it (in the Morgan, above it in the Vienna) reads: "elaphou kephale" - and I am lead to believe (by a third, knowledgable source) the text actually deals with a kind of aphrodisiac tuber/fungus. It's part of a section absent from most other copies of Dioscorides seminal work, so I haven't been able to locate a version either transcribed or translated. And, full disclosure, I have no level of Greek, least of all its medieval majuscule bookhand version, so I'm kind of stuck... TIA for any pointers or assistance! |
| Please click Here to read the full story. |
| |
| Other Top and Latest Questions: |
Trump administration equity stakes pose risks to U.S. companies and markets
|
The Trump administration equity portfolio is growing. These are the investments so far
|
Couple bought a 140-year-old New Jersey home for $550,000 and spent $172,000 renovating it—take a look inside
|
Here are the 5 big things we're watching in the stock market this week
|
Trump’s 'big beautiful bill' may spur significant changes to higher education in 2026 and the rise of 'un-college,' experts say
|
Hims & Hers pulls copycat weight-loss pill after threats of legal action
|
Washington Post publisher Will Lewis announces departure, following mass layoffs
|
Tech giants in China sold off alongside their U.S. peers last week. How to play it
|
U.S. plans initial payment towards billions owed to the UN, envoy Waltz says
|
Goldman Sachs says this under-the-radar biotech play could more than double in value
|